BioMarin Pharmaceutical (BMRN) : Mondays money flow points at investors jumping to buy the stock on the weakness of price. $7.05 million worth of transactions were on upticks, whereas, the downticks accounted for $6 million worth of transactions. The net money flow was a positive $1.06 million and the uptick to downtick ratio was 1.18. The net money flow into the stock was $1.14 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $1.14 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. BioMarin Pharmaceutical (BMRN) was trading at $90.86, down $1.22 during day. The stock slid -1.32% over the previous days close. For the week, the stock recorded -0.69% over the previous weeks close.
BioMarin Pharmaceutical Inc. is up 6.74% in the last 3-month period. Year-to-Date the stock performance stands at -11.36%. Shares of BioMarin Pharmaceutical Inc. rose by 4.82% in the last five trading days and 14.93% for the last 4 weeks. In a related news,The officer (EVP, General Counsel) of Biomarin Pharmaceutical Inc, Davis George Eric sold 2,167 shares at $90 on July 7, 2016. The Insider selling transaction had a total value worth of $195,030. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
BioMarin Pharmaceutical (NASDAQ:BMRN): stock turned positive on Monday. Though the stock opened at $92.23, the bulls momentum made the stock top out at $94.38 level for the day. The stock recorded a low of $89.57 and closed the trading day at $92.86, in the green by 0.85%. The total traded volume for the day was 2,381,621. The stock had closed at $92.08 in the previous days trading.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).